BioSpace News Archive

LimaCorporate proudly announces the FDA approval of a new shoulder platform focused on versatility and Operating Room efficiency.

Waters Corporation announced a combined investment of up to €6 million with support from IDA Ireland to expand its operations in Drinagh, Wexford to fund research and development of new clinical diagnostics products.

Massive Bio has been named a quarterfinalist in the annual UCSF | Health Hub: Digital Health Awards, which recognize health tech companies that are driving innovation and improving delivery of healthcare.

InVivo Therapeutics Holdings Corp. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock.

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 6-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announces today that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value.

The United Steelworkers union (USW) is encouraging Ontario miners diagnosed with amyotrophic lateral sclerosis (ALS) or motor neuron diseases (MNDs) to participate in crucial research to confirm whether the diseases are occupational illnesses that qualify for compensation.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company’s common stock has been selling for a low price per share for a substantial period of time.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units to one new employee.